【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 407次   下载 314 本文二维码信息
码上扫一扫!
吲哚菁绿荧光染色在肝胆胰恶性肿瘤转移中的应用研究进展
杨施晔1,2,郭磊1,郭卫星1*
0
(1. 海军军医大学(第二军医大学)第三附属医院肝外六科, 上海 200438;
2. 南通大学第二附属医院(南通市第一人民医院)综合外科, 南通 226014
*通信作者)
摘要:
肝胆胰肿瘤是消化系统的高发疾病,其恶性程度较高,临床预后较差。这一不良预后状况的主要原因为手术治疗中较难做到根治性切除和足够范围的淋巴结清扫,从而导致肿瘤容易复发、转移。吲哚菁绿荧光染色以往多被应用于肝功能和肝有效血量的检测,近年来逐渐被推广应用于肝胆胰恶性肿瘤术中转移灶的监测与诊疗,以达到更好的手术根治效果。本文结合相关文献,就吲哚菁绿荧光染色在肝胆胰恶性肿瘤转移中的应用研究进展进行综述。
关键词:  吲哚菁绿荧光染色  肝胆胰肿瘤  肿瘤转移  疾病监测
DOI:10.16781/j.CN31-2187/R.20220142
投稿时间:2022-02-18修订日期:2023-03-20
基金项目:孟超人才培养计划(EHBH2019YC112),南通市卫生健康委员会青年课题(QNZ2023032).
Application of indocyanine green fluorescence staining in hepatobiliary and pancreatic malignant tumor metastasis: research progress
YANG Shiye1,2,GUO Lei1,GUO Weixing1*
(1. Department of Hepatic Surgery (Ⅵ), The Third Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200438, China;
2. Department of Comprehensive Surgery, The Second Affiliated Hospital of Nantong University (First People's Hospital of Nantong), Nantong 226014, Jiangsu, China
*Corresponding author)
Abstract:
Hepatobiliary and pancreatic tumors are high-incidence diseases of the digestive system with high malignancy and poor clinical prognosis. Failure to achieve radical resection and sufficient dissection of lymph nodes during surgical treatment is the main reason for tumor recurrence and metastasis. Indocyanine green (ICG) fluorescence staining has been commonly used in the detection of liver function and the evaluation of effective liver blood volume in the past. In recent years, it has been gradually applied to the intraoperative diagnosis, treatment and monitoring of hepatobiliary and pancreatic tumor metastases, in order to achieve better radical results of surgery. This paper reviews the application of ICG fluorescence staining in hepatobiliary and pancreatic tumor metastases based on related literatures.
Key words:  indocyanine green fluorescence staining  hepatobiliary and pancreatic neoplasms  neoplasm metastasis  disease monitoring